The influence of fluvastatin on the levels of IL-6 ,MMP-1 and APN in patients with coronary heart diseases

( views:352, downloads:0 )
Author:
LYU Jing-yi(Department of Internal Medicine ,the Geological Minerals Worker's Hospital of Shandong,Jinan, Shandong 250013, China)
LI Hong-xia()
Journal Title:
Chinese Journal of Primary Medicine and Pharmacy
Issue:
Volume 19, Issue 20, 2012
DOI:
10.3760/cma.j.issn.1008-6706.2012.20.008
Key Word:
Coronary heart diseases ; Interleukin-6 ; Matrixmetalloproteinase-1 ; APN ; Fluvastatin

Abstract: Objective To explore the influence of fluvastatin on the levels of IL-6,MMP-1 and APN in patients with coronary heart diseases.Methods 60 patients with coronary heart diseases were randomly divided into 2groups:40mg group and 80mg group treated by fluvastatin and 30 healthy persons were selected as control group,serum levels of IL-6,MMP-1 and APN were measured before and after treatmead.Results Serum levels of IL-6,MMP-1 were significantly increasd in the coronary heart diseases group (t =4.896,4.231,all P < 0.05 ).Serum level of APN was significantly decreasd in the coronary heart diseases group( t =4.352,P < 0.05 ).The serum levels of IL-6and M MP-1 were significantly decreasd after therapy (4.156,4.121、4.553,all P < 0.05 ).The decrease of serum levels of IL-6,MMP-1 in 80mg group was more significant than those of 40mg group( t =3.786,3.690,4.10,all P <0.05).Conclusion Serum concentrations of IL-6 and MMP-1 increase,but APN decrease in patients with coronary heart diseases.Serum concentrations of IL-6,MMP-1 and APN had relationships with coronary plaque extent.Fluvastatin could decrease serum levels of IL-6 and MMP-1,increase serum level of APN in patients with coronary heart diseases,and have a beneficial effect on steadying the plaque.

  • [1]叶任高,陆再英,谢毅,等.内科学.6版.北京:人民卫生出版社,2004:283-285.
  • [2]杨水祥,胡大一.动脉粥样硬化与血管疾病危险因子重要概念回顾.中国心血管病研究,2004,2(5):317-319.
  • [3]王晓华,冯慧,刘树琴.急性冠脉综合征患者血清高敏C-反应蛋白与白介素-6的相关性研究.中国基层医药,2010,17(24):3363-3365.
  • [4]陈燕,陈慧.基质金属蛋白酶-9与易损斑块.心血管康复医学杂志,2007,16(1):96-98.
  • [5]Ryuichi K,Yukihiko M.Levels of Matrix metalloproteinase-1 in patints with and without coronary complex and noncomplex coronary plaques.Am J Cardiol,2005,9(1):90-92.
  • [6]张鹏,汪南平.脂联素与心血管疾病.生理科学进展,2007,38(2):149-152.
  • [7]刘岩,邹大迸,李慧,等.低脂联素血症是冠状动脉粥样硬化严重程度的重要指标.中华内分泌代谢杂志,2007,21(2):5-8.
  • [8]赵水平.他汀类药物抗炎防治动脉粥样硬化.中华医学杂志,2005,85(40):2818-2820.
  • [9]宋军,吴爱峰,王德帅,等.他汀类药物稳定动脉粥样硬化斑块的作用与机制.中国基层医药,2010,17(1):63-64.
  • [10]郑刚,张承宗.解读急性冠状动脉综合征他汀类药物治疗作用的临床证据.中国心血管病研究,2004,2(6):406-409.
  • [11]杨明.两种不同剂量脂必泰与氟伐他汀降脂疗效观察.中国基层医药,2011,18(13):1843-1844.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn